Posizioni attive di Howard Davis
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Direttore/Membro del Consiglio | 11/08/2022 | - |
| Amministratore Delegato | 11/08/2022 | - |
Storia della carriera di Howard Davis
Precedenti posizioni note di Howard Davis
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| THIRD HARMONIC BIO, INC. | Direttore operativo | - | - |
Statistiche
Distribuzione geografica
| Stati Uniti | 2 |
| Regno Unito | 2 |
Posizioni
| Chief Operating Officer | 1 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Settori
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| THIRD HARMONIC BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Howard Davis
- Esperienza
